Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
The efficacy and safety of intravenous topotecan (hycamtin) given in a dose of 4 mg/m2 on days of 1, 8, 15 of a 28-day cycle of its therapy were evaluated in patients with recurrent ovarian cancer (OC).Preliminary analysis of the safety and toxicity of the topotecan regimen demonstrated no impact on...
Main Authors: | E. G. Novikova, I. A. Korneyeva, E. Yu. Moskovskaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/152 |
Similar Items
-
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014-07-01) -
Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life
by: E. G. Novikova, et al.
Published: (2014-08-01) -
Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
by: I. A. Pokataev, et al.
Published: (2015-11-01) -
The role of topotecan in cancer ginecology treatment
by: A. G. Kedrova, et al.
Published: (2017-02-01) -
DIAGNOSTIC VALUE OF ULTRASOUND EXAMINATION IN PREOPERATIVE STAGING OF DISSEMINATED OVARIAN CANCER
by: N. V. Vyatkina, et al.
Published: (2016-10-01)